 |
|
A Comparison of the Effectiveness of Three Regimens in the Prevention of Pneumocystis carinii Pneumonia in Human Immunodeficiency Virus-Infected Patients
Maureen A. Martin, FNP-C, MN;
Patricia H. Cox, FNP-C, MN, MPH;
Keith Beck, MD;
Cathryn M. Styer, FNP-C, MN;
Gildon N. Beall, MD
Arch Intern Med. 1992;152(3):523-528.
Abstract
Background.—
Pneumocystis carinii pneumonia (PCP) is a major cause of morbidity and the leading cause of death in patients with the acquired immunodeficiency syndrome. The prevention of the occurrence and recurrence of PCP is a cornerstone in the treatment of patients infected with the human immunodeficiency virus. There are few studies comparing PCP prophylactic regimens.
Methods.—
The efficacy of three regimens for prophylaxis against PCP was assessed in a retrospective chart review of 211 human immunodeficiency virus—infected patients at risk for the disease. Over the course of the 2-year study period, 133 patients were prescribed trimethoprimsulfamethoxazole (one double-strength tablet twice a day, thrice weekly) for a mean of 7.4 months (range, 1 to 25 months). Seventy-seven patients received dapsone (50 mg daily) for a mean of 5.7 months (range, 1 to 23 months), and 125 patients received aerosolized pentamidine (300 mg via nebulizer once monthly) for a mean of 9.3 months (range, 1 to 21 months). The majority of patients (62%) received primary prophylaxis; 38% had one or more previous episodes of PCP; and 73% were receiving concomitant antiretroviral therapy.
Results.—
PneumocystisPneumocystis carinii pneumonia did not develop in any patient receiving trimethoprimsulfamethoxazole in 981 patient-months. Five patients receiving dapsone for 437 patient-months and 17 patients receiving aerosolized pentamidine for 1166 patient-months developed PCP. Fifty-six percent of the trimethoprimsulfamethoxazole group and 55% of the dapsone group changed drug due to adverse reactions, while only 2% in the aerosolized pentamidine group required drug change.
Conclusion.—
Despite its adverse reaction profile, trimethoprim-sulfamethoxazole is the most effective agent to prevent the occurrence and recurrence of PCP.
(Arch Intern Med. 1992;152:523-528)
Author Affiliations
From the Department of Medicine, Divisions of General Internal Medicine and Allergy and Clinical Immunology, Harbor-UCLA Medical Center, Torrance, Calif.
Footnotes
Accepted for publication November 27, 1991.
Poster presentation at the Seventh International Conference on AIDS, June 17-18, 1991, Florence, Italy.
Reprints not available.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
High Rates of Pneumocystis carinii Pneumonia in Allogeneic Blood and Marrow Transplant Recipients Receiving Dapsone Prophylaxis
Souza et al.
Clinical Infectious Diseases 1999;29:1467-1471.
ABSTRACT
| FULL TEXT
Who Should Be Screened for HIV Infection? A Cost-effectiveness Analysis
McCarthy et al.
Arch Intern Med 1993;153:1107-1116.
ABSTRACT
Comparing Pneumocystis carinii Pneumonia Prophylactic Regimens-Reply
Martin et al.
Arch Intern Med 1993;153:783-783.
ABSTRACT
Comparing Pneumocystis carinii Pneumonia Prophylactic Regimens
Khaliq and Lamp
Arch Intern Med 1993;153:782-783.
ABSTRACT
Preventive Health Care for Adults With HIV Infection
Jewett and Hecht
JAMA 1993;269:1144-1153.
ABSTRACT
WHAT PROPHYLAXIS IS BEST AGAINST PNEUMOCYSTIS PNEUMONIA
JWatch General 1992;1992:4-4.
FULL TEXT
|
